TOP TEN perturbations for 1139_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1139_at
Selected probe(set): 224761_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1139_at (224761_at) across 6672 perturbations tested by GENEVESTIGATOR:

brefeldin A study 1 (0.5ug/ml; HCT 116) / untreated HCT 116 cell sample

Relative Expression (log2-ratio):3.2817783
Number of Samples:3 / 3
Experimental brefeldin A study 1 (0.5ug/ml; HCT 116)
Human colon carcinoma cell line HCT116 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated HCT 116 cell sample
Human colon carcinoma cell line HCT116 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

brefeldin A study 1 (0.5ug/ml; p53HCT116) / untreated p53HCT116 cell sample

Relative Expression (log2-ratio):3.1765528
Number of Samples:2 / 3
Experimental brefeldin A study 1 (0.5ug/ml; p53HCT116)
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated p53HCT116 cell sample
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

glioma study 27 (glioblastoma, NOS) / glioma study 27 (pilocytic astrocytoma)

Relative Expression (log2-ratio):2.7291594
Number of Samples:4 / 2
Experimental glioma study 27 (glioblastoma, NOS)
Primary tumor samples from resected brain tissues of patients with glioblastoma, NOS(WHO grade IV astrocytoma).
Control glioma study 27 (pilocytic astrocytoma)
Primary tumor samples from resected brain tissues of patients with pilocytic astrocytoma (WHO grade I astrocytoma).

glioma study 27 (astrocytoma, NOS) / glioma study 27 (pilocytic astrocytoma)

Relative Expression (log2-ratio):2.5939407
Number of Samples:5 / 2
Experimental glioma study 27 (astrocytoma, NOS)
Primary tumor samples from resected brain tissues of patients with astrocytoma, NOS (WHO grade II astrocytoma).
Control glioma study 27 (pilocytic astrocytoma)
Primary tumor samples from resected brain tissues of patients with pilocytic astrocytoma (WHO grade I astrocytoma).

R547 study 1 (24h) / vehicle (DMSO) treated DU145 cell sample

Relative Expression (log2-ratio):-2.5245008
Number of Samples:2 / 4
Experimental R547 study 1 (24h)
Human prostate carcinoma metastatic cell line DU145 treated with the CDK inhibitor R547 [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl]-(2, 3-difluoro-6-methoxyphenyl)methanone (Hoffmann-La Roche compound) for 24 hours at a 3xIC90 concentration of 5.1 ╬╝mol/L. ATC code:---
Control vehicle (DMSO) treated DU145 cell sample
Human prostate carcinoma metastatic cell line DU145 treated with vehicle (DMSO) for 24 hours.

glioma study 27 (astrocytoma, anaplastic) / glioma study 27 (pilocytic astrocytoma)

Relative Expression (log2-ratio):2.182126
Number of Samples:6 / 2
Experimental glioma study 27 (astrocytoma, anaplastic)
Primary tumor samples from resected brain tissues of patients with anaplastic astrocytoma(WHO grade III astrocytoma).
Control glioma study 27 (pilocytic astrocytoma)
Primary tumor samples from resected brain tissues of patients with pilocytic astrocytoma (WHO grade I astrocytoma).

renal cell carcinoma study 6 (chromophobe type) / normal kidney tissue

Relative Expression (log2-ratio):-2.1370811
Number of Samples:4 / 2
Experimental renal cell carcinoma study 6 (chromophobe type)
Tumor tissue samples from the kidney of patients with chromophobe renal cell carcinoma (cRCC).
Control normal kidney tissue
Normal fetal kidney tissue samples.

kidney transplantation study 15 (8 week) / normal monocyte (CD14+) sample

Relative Expression (log2-ratio):-2.124402
Number of Samples:2 / 5
Experimental kidney transplantation study 15 (8 week)
CD14+ monocyte samples derived from kidney transplant patients 8 weeks post-transplantation. Samples were collected 8 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control normal monocyte (CD14+) sample
CD14+ monocyte samples derived from healthy control subjects.

C. pneumoniae study 1 / uninfected monocyte-derived dendritic cell sample

Relative Expression (log2-ratio):2.092476
Number of Samples:2 / 2
Experimental C. pneumoniae study 1
Monocyte-derived dendritic cells from healthy donors were infected with Chlamydia pneumoniae at a multiplicity of infection of 5 for 72 h.
Control uninfected monocyte-derived dendritic cell sample
Uninfected monocyte-derived dendritic cells from healthy donors.

4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone study 1 (10000 uM; Hep-G2) / vehicle (PBS) treated Hep-G2 cell sample

Relative Expression (log2-ratio):1.9551144
Number of Samples:3 / 6
Experimental 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone study 1 (10000 uM; Hep-G2)
Hep-G2 cells exposed to 10000 uM 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (dissolved in PBS) for 72 hours. Cells were exposed to the chemical when 80% confluence was reached. Cells were treated with the IC10 determined by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide test (number of replicates, n = 3). ATC code:---
Control vehicle (PBS) treated Hep-G2 cell sample
Hep-G2 cells treated with vehicle (PBS) for 72 hours. Cells were exposed to the vehicle when 80% confluence was reached.